|
Tarlatamab
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer.[4] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.[4] The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.[5] Tarlatamab was approved for medical use in the United States in May 2024.[5][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7] Medical usesTarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.[4][5] Adverse effectsThe prescribing information for tarlatamab includes a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).[4] The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.[5] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.[5] HistoryEfficacy was evaluated in 99 participants with relapsed/refractory extensive stage small cell lung cancer with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study.[5] Participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded.[5] Participants received tarlatamab until disease progression or unacceptable toxicity.[5] The FDA granted the application for tarlatamab priority review, breakthrough therapy, and orphan drug designations.[5] Society and cultureLegal statusTarlatamab was approved for medical use in the United States in May 2024.[5][6][8][9] NamesTarlatamab is the international nonproprietary name[10] and the United States Adopted Name.[11] References
Further reading
External links
|
||||||||||||||||||||||||||||||||||||||||||||
